BioNTech's (BNTX) Buy Rating Reiterated at Truist Financial

Truist Financial reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $155.00 target price on the stock, up from their prior target price of $151.00.

Several other research firms have also recently weighed in on BNTX. Citigroup reiterated a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $134.00 price objective on shares of BioNTech in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $139.14.

BioNTech Trading Down 3.9%

NASDAQ BNTX traded down $4.50 on Tuesday, hitting $111.14. The company's stock had a trading volume of 1,532,837 shares, compared to its average volume of 939,050. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company's 50-day moving average is $98.19 and its 200 day moving average is $108.26. The firm has a market cap of $26.72 billion, a PE ratio of -52.92 and a beta of 1.29.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same period in the prior year, the company posted $1.90 EPS. The company's revenue was down 19.5% on a year-over-year basis. As a group, analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new position in shares of BioNTech in the first quarter valued at $167,000. Millennium Management LLC lifted its stake in shares of BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company's stock valued at $49,625,000 after buying an additional 390,360 shares in the last quarter. Banque Transatlantique SA bought a new position in shares of BioNTech in the first quarter valued at $80,000. Alyeska Investment Group L.P. lifted its position in shares of BioNTech by 2,769.2% during the first quarter. Alyeska Investment Group L.P. now owns 75,000 shares of the company's stock valued at $6,830,000 after purchasing an additional 72,386 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of BioNTech during the first quarter valued at about $455,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.